Dyslipidemias, Oxidative Stress
Conditions
Keywords
Octacosanol, Taekwondo, Lipid Profiles, Oxidative Stress
Brief summary
Taekwondo players undergo rapid reductions of body weight prior to their competition in order to gain a size advantage over the opponent. However, these large weight changes with concomitant high intensity exercise training induce poor lipid profiles and high levels of oxidative stress, which can be detrimental to health and sports performance. Therefore, the purpose of this study was to investigate the ability of the nutritional supplement octacosanol to combat the physiological detriments that can occur from these rapid weight changes paired with high intensity exercise training.
Detailed description
Athletes that participate in weight division sports such as taekwondo, boxing, judo, and wrestling regularly reduce their body weight severely prior to competition in order to gain a size advantage over the opponent while simultaneously meeting their weight division requirements. In general, athletes have acute weight loss of 4-7 kg within 3-4 days of competition, while longer periods of more gradual weight loss of 15-22 kg lasting 3-4 weeks. Although this kind of extreme weight loss can induce metabolic dysfunction, it is repeatedly performed by athletes of weight division sports in order to acquire a more advantageous condition for play. Furthermore, athletes participating in matches tend to obtain excessive weights compared to their weight division during the offseason in order to lift heavier weights during training, and then rapidly lose that weight over a short period of time prior to competition, resulting in the deterioration of physiological function and possibly sports performance. Rapid weight loss with high intensity exercise training also increases oxygen free radical production to a point that exceeds the defense mechanism of antioxidant enzymes in the body and ultimately results in damage to the cells, specifically, the lipid peroxidation of cell membranes. Not only does this decrease physiological function, but sports performance can also decrease as oxidative stress increases due to an interference in metabolic activity, a reduction in vascular function and an increase in systemic inflammation. Octacosanol, a straight-chain, high-molecular-weight, primary aliphatic alcohol minimally contained in the germinal disks of rice bran, wheat and sugar cane, may be able to prevent these deteriorations as it has been shown to provide various health benefits. In fact, previous studies reported that pre-exercise octacosanol intake contributed to enhanced muscular strength, muscular endurance and oxygen transport ability. Additionally, octacosanol supplementation has been shown to improve cardiovascular endurance and heart function in patients with peripheral artery disease, improve levels of low-density and high-density lipoprotein-cholesterol in patients with hypercholesterolemia, and increase glycogen accumulation in mice9. However, the potential beneficial effects of octacosanol intake for reducing free radical production and preventing detrimental physiological function from excessive weight loss with high intensity exercise has not been examined. Thus, the purpose of this study was to investigate the effects of octacosanol supplementation during acute weight loss with high-intensity exercise training on lipid profiles and markers of oxidative stress in taekwondo players.
Interventions
One capsules (20-mg) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed twice a day
A placebo pill was taken twice a day in a double-blinded method at the same frequency and time as the octacosanol supplement
Sponsors
Study design
Eligibility
Inclusion criteria
* at least 3 years of experience in national taekwondo competitions * abstain from caffeinated drinks, alcohol, and antioxidant supplements during the whole period of the study
Exclusion criteria
* no history of chronic use of antioxidants, chronic aspirin, and nonsteroidal anti-inflammatory drugs (NSAIDs) * No cardiovascular, neurological, metabolic or renal diseases * no musculoskeletal injuries
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Triglycerides | 6 days | Plasma triglyceride levels |
| Total Cholesterol | 6 days | Plasma total cholesterol levels |
| High-density Lipoprotein | 6 days | Plasma levels of high-density lipoprotein |
| Low-density Lipoprotein | 6 days | Plasma levels of low-density lipoprotein |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Superoxide Dismutase | 6 days | Plasma levels of superoxide dismutase |
| Glutathione Peroxidase | 6 days | Plasma levels of glutathione peroxidase |
| Malondialdehyde | 6 days | Plasma levels of malondialdehyde |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Octacosanol Two capsules (20-mg x 2) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed daily by the octacosanol group for six days, one capsule 30 minutes after morning and afternoon meals.
Octacosanol: One capsules (20-mg) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed twice a day | 13 |
| Placebo A placebo pill was taken twice daily in replacement of the octacosanol supplement
Placebo: A placebo pill was taken twice a day in a double-blinded method at the same frequency and time as the octacosanol supplement | 13 |
| Total | 26 |
Baseline characteristics
| Characteristic | Placebo | Total | Octacosanol |
|---|---|---|---|
| Age, Continuous | 18 years STANDARD_DEVIATION 1 | 18 years STANDARD_DEVIATION 1.3 | 18 years STANDARD_DEVIATION 1 |
| Body fat | 8 percentage of body fat STANDARD_DEVIATION 2 | 8 percentage of body fat STANDARD_DEVIATION 2.4 | 8 percentage of body fat STANDARD_DEVIATION 2 |
| Height | 173.9 cm STANDARD_DEVIATION 6.3 | 174.3 cm STANDARD_DEVIATION 3.9 | 174.7 cm STANDARD_DEVIATION 1.4 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 13 Participants | 26 Participants | 13 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 0 Participants | 0 Participants | 0 Participants |
| Region of Enrollment South Korea | 13 Participants | 26 Participants | 13 Participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 13 Participants | 26 Participants | 13 Participants |
| Weight | 66.7 kg STANDARD_DEVIATION 5.7 | 66.8 kg STANDARD_DEVIATION 6.2 | 66.9 kg STANDARD_DEVIATION 6.7 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 13 | 0 / 13 |
| other Total, other adverse events | 0 / 13 | 0 / 13 |
| serious Total, serious adverse events | 0 / 13 | 0 / 13 |
Outcome results
High-density Lipoprotein
Plasma levels of high-density lipoprotein
Time frame: 6 days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Octacosanol | High-density Lipoprotein | 71 mg/dL | Standard Deviation 4.4 |
| Placebo | High-density Lipoprotein | 49.2 mg/dL | Standard Deviation 2.6 |
Low-density Lipoprotein
Plasma levels of low-density lipoprotein
Time frame: 6 days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Octacosanol | Low-density Lipoprotein | 92.6 mg/dL | Standard Deviation 8.1 |
| Placebo | Low-density Lipoprotein | 114.9 mg/dL | Standard Deviation 10.8 |
Total Cholesterol
Plasma total cholesterol levels
Time frame: 6 days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Octacosanol | Total Cholesterol | 164 mg/dL | Standard Deviation 12.8 |
| Placebo | Total Cholesterol | 173.5 mg/dL | Standard Deviation 16.1 |
Triglycerides
Plasma triglyceride levels
Time frame: 6 days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Octacosanol | Triglycerides | 34.9 mg/dL | Standard Deviation 7.8 |
| Placebo | Triglycerides | 110 mg/dL | Standard Deviation 8.1 |
Glutathione Peroxidase
Plasma levels of glutathione peroxidase
Time frame: 6 days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Octacosanol | Glutathione Peroxidase | 66.9 U/gHb | Standard Deviation 10.8 |
| Placebo | Glutathione Peroxidase | 47.1 U/gHb | Standard Deviation 9.7 |
Malondialdehyde
Plasma levels of malondialdehyde
Time frame: 6 days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Octacosanol | Malondialdehyde | 0.25 mmol/mL | Standard Deviation 0.1 |
| Placebo | Malondialdehyde | 0.93 mmol/mL | Standard Deviation 0.12 |
Superoxide Dismutase
Plasma levels of superoxide dismutase
Time frame: 6 days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Octacosanol | Superoxide Dismutase | 1450 U/gHb | Standard Deviation 138.9 |
| Placebo | Superoxide Dismutase | 1010 U/gHb | Standard Deviation 150.1 |